During the last session, Arcus Biosciences Inc. (NYSE:RCUS)’s traded shares were 1.01 million, with the beta value of the company hitting 0.87. At the end of the trading day, the stock’s price was $17.50, reflecting an intraday loss of -3.05% or -$0.55. The 52-week high for the RCUS share is $36.13, that puts it down -106.46 from that peak though still a striking 10.29% gain since the share price plummeted to a 52-week low of $15.70. The company’s market capitalization is $1.23B, and the average intraday trading volume over the past 10 days was 0.86 million shares, and the average trade volume was 975.28K shares over the past three months.

Arcus Biosciences Inc. (RCUS) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.80. RCUS has a Sell rating from 0 analyst(s) out of 12 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 9 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$1.15.

Arcus Biosciences Inc. (NYSE:RCUS) trade information

Arcus Biosciences Inc. (RCUS) registered a -3.05% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.05% in intraday trading to $17.50 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is -0.62%, and it has moved by -2.72% in 30 days. Based on these gigs, the overall price performance for the year is -2.51%. The short interest in Arcus Biosciences Inc. (NYSE:RCUS) is 7.81 million shares and it means that shorts have 10.44 day(s) to cover.

The consensus price target of analysts on Wall Street is $43.00, which implies an increase of 59.3% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $22.00 and $70.00 respectively. As a result, RCUS is trading at a discount of -300.0% off the target high and -25.71% off the low.

Arcus Biosciences Inc. (RCUS) estimates and forecasts

Statistics show that Arcus Biosciences Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Arcus Biosciences Inc. (RCUS) shares have gone down -35.59% during the last six months, with a year-to-date growth rate less than the industry average at -19.41% against 11.40. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to shrink -23.70% this quarter and then drop -30.00% in the quarter after that. In the rating firms’ projections, revenue will decrease -9.80% compared to the previous financial year.

Revenue for the current quarter is expected to be $26.23 million as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to $25.87 million by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $26.76 million and $21.89 million respectively. In this case, analysts expect current quarter sales to shrink by -2.00% and then jump by 18.20% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.80%. While earnings are projected to return -619.20% in 2023.

RCUS Dividends

Arcus Biosciences Inc. is due to release its next quarterly earnings between August 01 and August 07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Arcus Biosciences Inc. (NYSE:RCUS)’s Major holders

Arcus Biosciences Inc. insiders own 28.67% of total outstanding shares while institutional holders control 75.68%, with the float percentage being 106.10%. Blackrock Inc. is the largest shareholder of the company, while 291 institutions own stock in it. As of Mar 30, 2023, the company held over 10.14 million shares (or 13.87% of all shares), a total value of $184.94 million in shares.

The next largest institutional holding, with 5.5 million shares, is of State Street Corporation’s that is approximately 7.52% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $100.25 million.

Also, the Mutual Funds coming in first place with the largest holdings of Arcus Biosciences Inc. (RCUS) shares are iShares Core S&P Smallcap ETF and Fidelity Select Portfolios – Biotechnology. Data provided on Feb 27, 2023 indicates that iShares Core S&P Smallcap ETF owns about 3.94 million shares. This amounts to just over 5.40 percent of the company’s overall shares, with a $71.81 million market value. The same data shows that the other fund manager holds slightly less at 3.19 million, or about 4.37% of the stock, which is worth about $58.15 million.